Search research articles
Contact Us
Filters
Showing results (1-10 of 224) with videos related to
Page
of 23
Sort By:
Expert Review of Cardiovascular Therapy
|
June 12, 2013
Clinical end points in baroreflex activation therapy: what do we need to know?
Peter W de Leeuw, Abraham A Kroon
Journal of Hypertension
|
May 27, 2026
Chronic effects of baroreflex activation therapy: a tale of the unexpected
Peter W de Leeuw, Abraham A Kroon
Journal of Hypertension
|
November 1, 2018
A sluice to normotension?
Peter W de Leeuw, Abraham A Kroon
Expert Review of Medical Devices
|
November 11, 2025
Recent advances in device therapies for resistant hypertension. Where do we stand?
Peter W de Leeuw, Abraham A Kroon
Hypertension (Dallas, Tex. : 1979)
|
July 31, 2013
Salt and sensitivity
Peter W de Leeuw, Abraham A Kroon
The American Journal of Gastroenterology
|
November 11, 2005
A116C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension
Wilko Spiering, Abraham A Kroon, Peter W de Leeuw
Hypertension Research : Official Journal of the Japanese Society of Hypertension
|
January 20, 2017
The effects of missed doses of amlodipine and losartan on blood pressure in older hypertensive patients
Peter W de Leeuw, Robert Fagard, Abraham A Kroon
Cardiology Research and Practice
|
July 5, 2012
Baroreflex activation therapy for the treatment of drug-resistant hypertension: new developments
Teba Alnima, Peter W de Leeuw, Abraham A Kroon
Journal of the American College of Cardiology
|
May 16, 2006
Masked hypertension and white-coat hypertension prognosis
Willem Verberk, Abraham A Kroon, Peter W de Leeuw
European Journal of Pharmacology
|
May 20, 2015
Baropacing as a new option for treatment of resistant hypertension
Teba Alnima, Peter W de Leeuw, Abraham A Kroon
Page
of 23
Search research articles
Search
Showing results (1-10 of 224) with videos related to
Sort By:
Page
of 23
Expert Review of Cardiovascular Therapy
|
June 12, 2013
Clinical end points in baroreflex activation therapy: what do we need to know?
Peter W de Leeuw, Abraham A Kroon
Journal of Hypertension
|
May 27, 2026
Chronic effects of baroreflex activation therapy: a tale of the unexpected
Peter W de Leeuw, Abraham A Kroon
Journal of Hypertension
|
November 1, 2018
A sluice to normotension?
Peter W de Leeuw, Abraham A Kroon
Expert Review of Medical Devices
|
November 11, 2025
Recent advances in device therapies for resistant hypertension. Where do we stand?
Peter W de Leeuw, Abraham A Kroon
Hypertension (Dallas, Tex. : 1979)
|
July 31, 2013
Salt and sensitivity
Peter W de Leeuw, Abraham A Kroon
The American Journal of Gastroenterology
|
November 11, 2005
A116C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension
Wilko Spiering, Abraham A Kroon, Peter W de Leeuw
Hypertension Research : Official Journal of the Japanese Society of Hypertension
|
January 20, 2017
The effects of missed doses of amlodipine and losartan on blood pressure in older hypertensive patients
Peter W de Leeuw, Robert Fagard, Abraham A Kroon
Cardiology Research and Practice
|
July 5, 2012
Baroreflex activation therapy for the treatment of drug-resistant hypertension: new developments
Teba Alnima, Peter W de Leeuw, Abraham A Kroon
Journal of the American College of Cardiology
|
May 16, 2006
Masked hypertension and white-coat hypertension prognosis
Willem Verberk, Abraham A Kroon, Peter W de Leeuw
European Journal of Pharmacology
|
May 20, 2015
Baropacing as a new option for treatment of resistant hypertension
Teba Alnima, Peter W de Leeuw, Abraham A Kroon
Page
of 23